NAS
CLDX icon

Nykredit A/S’s Celldex Therapeutics CLDX Stock Holding History

Nykredit A/S’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.7K Buy
+1,793
New +$57.9K ﹤0.01% 1430

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nykredit A/S's CLDX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 1,793 shares worth $66.7K. The stake represents ﹤0.01% of the portfolio and ranks #1430 among its holdings.

155 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Nykredit A/S held 1,793 shares of Celldex Therapeutics worth $66.7K as of Q2 2026.
  • Celldex Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1430 holding.
  • 155 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.